BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study
BEBT-209 was a primary CDK4 selective inhibitor and showed an acceptable safety profile and dose-dependent plasma exposure. The results highlight the potential of combination treatments as compelling options, particularly in combination with fulvestrant.
Authors
- Huawu Xiao
- Xiaohong Yang (ORCID: https://orcid.org/0000-0001-6438-948X)
- Boni Ding (ORCID: https://orcid.org/0000-0003-1319-1398)
- Biao Wu (ORCID: https://orcid.org/0000-0002-2281-5193)
- Zhe-Yu Hu (ORCID: https://orcid.org/0000-0003-0932-9745)
- Binliang Liu (ORCID: https://orcid.org/0000-0002-3692-2272)
- Wei Li (ORCID: https://orcid.org/0000-0002-9991-7892)
- Jing Li (ORCID: https://orcid.org/0000-0002-6099-8349)
- Ying Wang (ORCID: https://orcid.org/0000-0003-2121-7025)
- Liping Liu (ORCID: https://orcid.org/0000-0001-7921-8018)
- Fan Zhang
- Ning Xie (ORCID: https://orcid.org/0000-0002-4628-2299)
- Yehui Shi
- Can Tian (ORCID: https://orcid.org/0000-0002-3675-4627)
- Quchang Ouyang (ORCID: https://orcid.org/0000-0003-1233-6081)
- Ke Jiang (ORCID: https://orcid.org/0000-0001-8369-1211)
- Shouman Wang
Institutions
- Central South University (CN)
- Nanchang University (CN)
- Sun Yat-sen University (CN)
- Jilin University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Hunan Cancer Hospital (CN)
- First Hospital of Jilin University (CN)
- Third Xiangya Hospital (CN)
- Xiangya Hospital Central South University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- The Breast
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1016/j.breast.2025.104527
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00